A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Asses the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donaperminogene seltoplasmid (Primary)
Indications Diabetic foot ulcer
Focus Therapeutic Use
Sponsors Helixmith

Most Recent Events

05 Jan 2023 Status changed from active, no longer recruiting to discontinued.
22 Oct 2021 According to a Helixmith media release, interim results of this trial were presented at the 2021 annual meeting of the Diabetic Foot Conference (DFCon).
22 Oct 2021 Interim results published in Helixmith Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight